A fluorogenic phospholipid for the detection of lysosomal phospholipase A2 activity
Akira Abe1, Piotr W Rzepecki, James A Shayman
1Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Analytical Biochemistry
|November 14, 2012
Summary
Researchers developed novel fluorescent phospholipid probes to detect lysosomal phospholipase A2 (LPLA2) activity. These probes enable quantitative measurement of LPLA2, aiding in understanding drug-induced phospholipidosis.
Area of Science:
- Biochemistry
- Enzymology
- Drug Discovery
Background:
- Lysosomal phospholipase A2 (LPLA2), also known as group XV PLA2, is implicated in drug-induced phospholipidosis.
- Existing methods for assessing LPLA2 activity are limited.
Purpose of the Study:
- To develop and validate novel fluorogenic phospholipid substrates for sensitive detection of LPLA2 activity.
- To utilize these substrates for quantifying LPLA2 and evaluating drug effects.
Main Methods:
- Synthesis of three fluorogenic phosphatidylglycerol (PG) substrates with quenched fluorophore-quencher pairs (FAM/DABCYL) or dual FAM labels.
- Utilized recombinant LPLA2 and mouse serum for enzymatic degradation assays.
- Quantified product formation via fluorescent measurements.
- Assessed the inhibitory effects of amiodarone and fluoxetine on LPLA2 activity.
Main Results:
- The synthesized substrate, 1-FAM-2-DABCYL-PG, demonstrated specific degradation by LPLA2 and mouse serum, but not by serum from LPLA2-deficient mice.
- Fluorescent measurements accurately quantified the formation of 1-FAM-lyso-PG.
- The IC(50) values for amiodarone and fluoxetine inhibiting LPLA2 were determined to be 10 μM and 19 μM, respectively.
Conclusions:
- 1-FAM-2-DABCYL-PG serves as a specific and effective substrate for LPLA2.
- This fluorogenic probe is a valuable tool for detecting LPLA2 activity in various biological samples.
- The developed method facilitates the study of LPLA2 in the context of drug-induced phospholipidosis.
